Bleeding and Thrombotic Adverse Events in Hospitalized Patients Under Empiric Treatment for Suspected Heparin-Induced Thrombocytopenia While Awaiting Confirmatory Testing
Research article published in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2021)
Resumen
Empiric management in suspected heparin-induced thrombocytopenia (HIT) is challenging due to imperfect prediction models, latency while awaiting test results and risks of empiric therapies. When there is high clinical suspicion for HIT, cessation of heparin and empiric non-heparin anticoagulation with FDA-approved argatroban is recommended. Alternatively off-label fondaparinux or watchful waiting have been utilized in clinical practice. Outcomes of patients empirically managed for HIT have not been compared directly in clinical trials and patients that ultimately do not have HIT are often overlooked. Clinicians need studies investigating empiric management to guide decision making in suspected HIT. In this study, adverse events (AE) were categorized and compared in patients being evaluated for HIT while undergoing empiric management by non-heparin anticoagulation with argatroban or fondaparinux, both at therapeutic or reduced doses, or watchful waiting with or without heparin. AE were defined as new thrombosis confirmed on imaging or new bleeding event after HIT was first suspected. A retrospective chart review of 312 patients tested for HIT at an academic hospital was conducted. 170 patients met inclusion criteria. Patients were excluded if the 4Ts score was < 4. The 4Ts score is a pretest probability for HIT based on thrombocytopenia degree, timing, alternative causes and presence of thrombosis. Included patients were divided according to management groups and compared with logistic regression analysis. Bleeding risk significantly differed between management groups (p = 0.002). Despite adjustment for bleeding risk, fondaparinux was associated with increased AE, (p = 0.03, OR = 5.81), while argatroban was not. There was no difference in AE based on time to initiation of empiric treatment and no advantage to reduced dosing with either anticoagulant. These findings challenge assumptions surrounding empiric HIT management.
Resumen tomado de PubMed (NCBI) para el registro citado, en el idioma original. La versión de referencia es la de la publicación original.
El resumen se deja sin traducir para conservar la redacción original de los autores.
Síntesis
A retrospective review of 170 hospitalized patients empirically treated for suspected HIT found bleeding risk differed significantly by management group (p=0.002); fondaparinux was linked to increased adverse events (OR=5.81, p=0.03), unlike argatroban, with treatment timing showing no effect on outcomes.
Por qué esto importa para la hirudoterapia
Esta revisión retrospectiva de historias clínicas de 170 pacientes (de 312 evaluados) examinó eventos adversos durante el manejo empírico de la trombocitopenia inducida por heparina (HIT) sospechada, comparando la anticoagulación no heparínica con el argatroban aprobado por la FDA, el fondaparinux fuera de etiqueta o la vigilancia expectante; el resumen reporta que el riesgo de sangrado difirió significativamente entre los grupos de manejo (p=0,002) y que, tras el ajuste, el fondaparinux estuvo asociado con eventos adversos aumentados (OR=5,81, p=0,03) mientras que el argatroban no. Para la hirudoterapia esto es relevante como contexto clínico para la inhibición de la trombina directa: el argatroban es un inhibidor directo de la trombina de pequeña molécula en la misma clase mecanística que la hirudina derivada de sanguijuela, y la HIT es precisamente el escenario donde se necesitan inhibidores libres de heparina, independientes del antitrombina III. Advertencia: este es un estudio retrospectivo de un solo hospital, no un RCT; compara fármacos en lugar de terapia de sanguijuelas y no puede probar la causalidad, por lo que solo informa el panorama de la evidencia del inhibidor de la trombina directa por analogía.
Compuestos relacionados del registro de la ASH
Fármacos sintéticos relacionados con el tema de este artículo. Actúan sobre las mismas dianas que las moléculas de la sanguijuela, pero no se derivan de la sanguijuela:
Citación
Bleeding and Thrombotic Adverse Events in Hospitalized Patients Under Empiric Treatment for Suspected Heparin-Induced Thrombocytopenia While Awaiting Confirmatory Testing.
Dykes et al. · Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2021
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Investigación relacionada
Más estudios revisados por pares en la categoría «Ensayos clínicos».
- Leech Therapy for Knee Osteoarthritis — The Landmark RCT — Michalsen et al. (2003)
- Leech-Assisted Flap Salvage — Systematic Review of 277 Cases — Whitaker et al. (2012)
- Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
- Efficacy and Safety of Hirudotherapy for Improving Sperm Quality Parameters in Male Infertility: A Randomized Controlled Trial — Abtahi-Forooshani M et al. (2026)
- Reverse Sural Flap Venous Congestion Successfully Managed With Enoxaparin in a Male Patient With a Traumatic Foot Crush Injury: A Case Report — Velasco-Bustamante J et al. (2026)
- Investigación de los efectos terapéuticos del tratamiento con sanguijuelas medicinales sobre la lesión por isquemia-reperfusión de la extremidad inferior — Ünal K et al. (2026)
- Efficacy of Medicinal Leech Therapy in Diverse Clinical Applications: A Comprehensive Study from Azerbaijan — Farzali S et al. (2025)
- HIRUDOTHERAPY IN RECONSTRUCTIVE SURGERY: CASE-REPORTS AND REVIEW — Heinz P et al. (2020)
- Hirudoterapia en la cicatrización de heridas — Nair H et al. (2022)
- Improvement of patient care through hirudotherapy and the management of leeches from their reception to their disposal in France — Vaesken C et al. (2023)
Añadido a la biblioteca ASH: 28 de mayo de 2026 · Última actualización del sitio: 18 de junio de 2026